Reduced-intensity versus myeloablative allogeneic transplantation
Hematology/Oncology and Stem Cell Therapy · 2017-10 · 10 (4) · 321-326
DOI: 10.1016/j.hemonc.2017.05.002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Hematology/Oncology and Stem Cell Therapy, 2017-10. Verfasst von Daniel J Weisdorf. Beteiligte Einrichtung: University of Minnesota, Department of Medicine, Division of Hematology, Oncology and Transplantation, 420 Delaware Street SE, MMC 480, Minneapolis, …. Hauptthemen laut MEDLINE: Graft Survival. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Allotransplantation cures patients by cytoreduction and the graft-versus-tumor (leukemia; graft-versus-leukemia [GVL]) alloresponse; both eliminate residual disease. The spectrum of conditioning intensity influences toxicities and non-relapse mortality. The spectrum of tumor sensitivity to the GVL response influences relapse. Balancing tolerable toxicities (influenced by patients’ performance status and comorbidities) is also influenced by the graft. Intense immunosuppression (for engraftment and graft-versus-host disease prevention) may constrain the immunologic potency of the graft and limit the antineoplastic capacity of the transplant, thus requiring more intense or more effective conditioning regimens to limit the risks of relapse and permit satisfactory disease-free survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Minnesota, Department of Medicine, Division of Hematology, Oncology and Transplantation, 420 Delaware Street SE, MMC 480, Minneapolis, MN 55455, United Sates. Electronic address: weisd001@umn.edu.
Zitieren
APA
Weisdorf, D. J. (2017). Reduced-intensity versus myeloablative allogeneic transplantation. Hematology/Oncology and Stem Cell Therapy, 10(4), 321-326. https://doi.org/10.1016/j.hemonc.2017.05.002
Vancouver
Weisdorf DJ. Reduced-intensity versus myeloablative allogeneic transplantation. Hematology/Oncology and Stem Cell Therapy. 2017;10(4):321-326. doi:10.1016/j.hemonc.2017.05.002
BibTeX
@article{Weisdorf2017,
author = {Weisdorf, Daniel J},
title = {Reduced-intensity versus myeloablative allogeneic transplantation},
journal = {Hematology/Oncology and Stem Cell Therapy},
year = {2017},
volume = {10},
number = {4},
pages = {321--326},
doi = {10.1016/j.hemonc.2017.05.002}
}
EUVIMED